Penumbra, Inc. (PEN)
Penumbra, Inc. is a global healthcare company specializing in innovative medical devices for neurovascular, peripheral vascular, and other neurological procedures. Founded in 2004, the company focuses on developing advanced solutions to improve patient outcomes and enhance procedural efficiency in minimally invasive treatments. Penumbra’s product portfolio includes devices for clot removal, aneurysm management, and vascular access, emphasizing technology-driven approaches in neurovascular and peripheral interventions.
Company News
Penumbra reported strong Q1 2025 earnings, with sales and thrombectomy revenue growth exceeding expectations. The company is well-insulated from tariff dynamics, with most of its manufacturing and raw materials sourced domestically. Analysts see further upside potential as the company executes on its growth strategy.
The virtual reality (VR) market is experiencing robust growth, driven by advancements in technology and broader adoption across various sectors, including gaming, education, healthcare, and enterprise. Standalone VR headsets are gaining popularity due to their convenience and mobility, while improvements in AI and haptic feedback are enhancing th...
Penumbra, a medical device company, has completed enrollment for a clinical trial of its latest thrombectomy product. An analyst at Truist Securities has also raised the company's price target, citing Penumbra's strong position in the neurological, venous, and thrombectomy segment.
Penumbra CEO Adam Elsesser sold 15,000 shares worth over $3 million, representing a portion of his holdings in the company. The transactions were carried out under a pre-arranged trading plan.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
